Scholars Central

Conference abstractPublished 3 Nov 2014

Mangafodipir(MnDPDP) from bench to bedside

Authors: Jan Olof G Karlsson

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Reactive oxygen species (ROS) and reactive nitrogen species (RNS) participate in tissue damage, caused by e.g., ischemiareperfusion, inflammation, drugs and radiation. The mitochondrial superoxide dismutase (MnSOD) plays a key role in keeping ROS and RNS in check. During development of MnDPDP as an MRI contrast agent it was serendipitously discovered that MnDPDP and its metabolite MnPLED possessed MnSOD mimetic activity. Subsequently it was shown that it protected mice against serious side effects of several chemotherapy drugs, without interfering negatively with the anticancer effect. The compound was first tried in a colon cancer patient going through palliative treatment with 5-FU plus oxaliplatin.A first clinical feasibility study in colon cancer patients going through adjuvant 5-FU plusoxaliplatinreported promising results in 2012. This was followed by another clinical feasibility study showing encouraging results when it comes to treatment of neuropathy caused by oxaliplatin.MnPLED hasfurthermore been shown to reduce myocardial infarction size in a pig model, and MnDPDP was recently tested as an adjunct to PCI in patients with ST-elevated myocardial infarctions, with promising results. MnDPDP has also been shown protect mice against acetaminophen-induced liver failure. Whereas MRI contrast depends on release of Mn2+, the MnSOD mimetic activity depends on Mn2+ still bound to DPDP or PLED. Calmangafodipir [Ca4Mn(DPDP)5] is stabilized with respect to Mn2+ and has at equimolar Mn2+ doses superior therapeutic activity in comparison to MnDPDP. Ca4Mn(DPDP)5 is at present explored as a chemotherapy adjunct in a clinical multicenter phase II study in patients with metastatic colorectal cancer.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Translational Medicine.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalTranslational Medicine
  • SubjectGeneral & Internal Medicine
  • BylineArticles whose byline prints “Jan Olof G Karlsson”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels